BrainsWay (NASDAQ:BWAY) Issues Earnings Results

BrainsWay (NASDAQ:BWAY) issued its quarterly earnings data on Tuesday. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03, Zacks reports. BrainsWay had a net margin of 3.88% and a return on equity of 3.56%. The business had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Stock Performance

Shares of NASDAQ:BWAY traded down $0.66 during trading on Wednesday, reaching $9.04. The stock had a trading volume of 159,185 shares, compared to its average volume of 95,657. The business has a fifty day moving average price of $9.11 and a 200-day moving average price of $7.40. BrainsWay has a 1-year low of $3.80 and a 1-year high of $10.98. The stock has a market cap of $150.79 million, a PE ratio of 91.01 and a beta of 1.25.

Analyst Upgrades and Downgrades

BWAY has been the topic of a number of recent analyst reports. Northland Securities increased their price target on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research report on Thursday, October 3rd. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of BrainsWay in a research note on Monday, October 21st.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.